U se of a Low Molecular Weight Preparation of Heparin ORG 10172 (Lomoparan) in the Critically III Unfractionated heparin (UFH) has been in use for more than fifty years. I However, it cannot be used as an anticoagulant in clinical situations where there is hypersensitivity and/or a significant risk of bleeding. Low molecular weight preparation of heparins and heparinoids are a relatively new group of compounds which provide adequate anticoagulation without increasing the risk of bleeding. We report the use of an investigative low molecular weight glycosaminoglycuronan, Lomoparan (ORG 10172), in two patients in our intensive care unit where UFH could not be used.
CASE REPORTS Patient 1. A 58-year-old man developed wound infection and septic shock after a highly selective vagotomy performed in another hospital. He developed multiple system failure and was transferred to our Intensive Care Unit four days later. Continuous veno-venous haemofiltration (CVVH) was started for renal support but five circuits clotted in 40 hours despite the use of adequate UFH (up to 38,000 IU per day and an activated partial thromboplastin time, APTT, of89 seconds). Lomoparan was then commenced with a bolus of 2500 units and an additional dose of 1250 units for priming the circuit. The maintenance infusion was 200-400 units per hour. On this regimen, his next haemofiltration circuit was electively changed after five days and his subsequent one after three days following which he was started on intermittent haemodialysis without anticoagulation since further supplies of Lomoparan were unavailable. His prothrombin time (PT) values ranged between 11 to 15 seconds and his APTT from 25 to 42 seconds. Anti Factor Xa activity and the corresponding Lomoparan dose are shown in the graph (Figure 1 ). The patient continued to deteriorate and died 22 days post surgery. Autopsy revealed that death was due to acute coronary insufficiency. Although no recent necrosis or scarring was seen, the right coronary artery had evidence of recent haemorrhage into an atherosclerotic plaque with almost complete occlusion of the lumen of the artery. There was no other evidence of haemorrhage.
Patient 2. A 59-year-old woman who was on therapy for hypothyroidism had a mitral valve replacement for rheumatic valvular disease. She had a perioperative myocardial infarct and her clinical course was complicated by dysrhythmias and acute renal failure. Intraoperatively she received UFH followed postoperatively as an infusion at a dose of 600-1000U/hour and was transferred to the ICU for CVVH. She developed thrombocytopenia on the ninth day after her surgery (her platelet count was 317,000 X 10 9 .1-I on admission and decreased to 41,000 X 10 9 .1-1 . Since heparin-induced thrombocytopenia was considered to be a strong possibility, UFH was stopped and Lomoparan was started. In view of the restricted supply of the product, she was given an initial intravenous dose of 1250 units and a maintenance dose of 1250 units subcutaneously one to three times per day ( Figure 2 ). Renal support was continued with CVVH initially, and later with intermittent haemodialysis without clotting in her extracorporeal circuit. Her platelet counts improved from the fourth day after stopping UFH and increased to 272,000 cm 3 on the tenth day. Her clinical course was complicated by Pseudomonas maltophilia septicaemia and recurrent arrythmias. Twenty-two days after admission to ICU she died, after developing a short episode of atrial fibrillation followed by cardiac asystole from which she could not be resuscitated. Autopsy showed a recent extensive transmural myocardial infarct, atrial thrombi, severe pulmomary oedema, cholestasis consistent with sepsis and lymphocyte thyroiditis. There was no evidence of haemorrhage. DISCUSSION Unfractionated heparin contains chains of 18 to 20 units varying in size from 5000-30,000 daltons with an average of 12,000-15,000 daltons. It exerts its major effect by binding to Antithrombin III (ATIII). 2 The heparin-AT III complex inhibits activated coagulation factors (lIa, IXa, Xa and XIa). However, it is now possible to separate the anti platelet and the anticoagulant actions of UFH. Shorter chains of 8 to 18 monosaccharides have been prepared (known as low molecular weight preparation of heparin-LMWH) with molecular weights varying from 2000 to 10,000 daltons (average 4000-6000). Unfractionated (high molecular weight) heparin has binding sites for platelets and antithrombin Ill. It causes a conformational change in AT III which inhibits factor lIa and Xa activity. In contrast, LMWHs have less than eighteen units -long enough to potentiate anti Xa inhibition by AT III but less adequate for thrombin inhibition. They also lack the binding sites for platelets. 3 In addition, LMWHs have been shown to inhibit prothrombinase (preventing the formation of thrombin) and to inactivate thrombin itself to varying extents. 4 The term 'low molecular weight preparation of heparin' is still poorly defined in spite of its frequent use and refers to a large number of similar preparations of varying pharmacological properties. Hence, experience with anyone preparation can be extrapolated to others only to a limited extent. The International Standard established by the World Health Organisation will reduce but not eliminate these problems, as factors other than anticoagulant activity may determine the clinical outcome. 5 LMWHs and LMWGs can be prepared by several methods,5,6 which include concentration of low molecular weight chains present in UFH, chemical or enzyme depolymerisation, or extraction from animal mucosa. The ability of these low molecular weight products to achieve adequate anticoagulation with less tendency to cause thrombocytopenia and bleeding is a distinct advantage. They also have a favourable pharmacokinetic profile for clinical use. However, they lack standard unitage. In addition, monitoring anticoagulant activity is as difficult as titrating the optimum dose. Protamine does not neutralise the activity of the LMWG Lomoparan and fresh frozen plasma should be used when needed. Protamine neutralises the in vitro activity of the LMWH Fragmin only partially (prolongation of APTT is fully neutralised but only 25-50% of the anti-Xa activity is neutralised). 5 However, the actual effect on bleeding in patients has yet to be determined. Clinical studies using LMWH preparations have been done in haemodialysis, haemofiltration, deep vein thrombosis (prophylaxis and treatment),12-16 ischaemic strokes,17-19 disseminated intravascular coagulation in acute promyelocytic leukemia 20 and in heparin-induced thrombocytopenia. 21 The dose depends on the preparation being used and the indication for which it is being used. The bioavailability of LMWH is high (greater than 90% after subcutaneous injection) and the biological half-life (measured as anti-Xa activity) is significantly longer than UFH 7 .22 but varies between the various preparations. The half-life of elimination of the plasma anti-Xa effect of ORG 10172 is 25 hours, the half-life of Fragmin is two to four hours and for Enoxaparin it is four hours. The elimination of LMWG is less dependent on the dose and route of administration and is a significant advantage over UFH since therapy can be simplified to twice daily subcutaneous dosing. Monitoring LMWG dosing is done by measuring anti Factor Xa activity: it is to be maintained between 0.2-0.6 U/ml in those with a risk of bleeding and 0.5-0.8 U/ml in those who have no risk of a bleed. The APTT should be within the normal range to prevent overdo sage as a prolonged APTT implies that toxic dose of LMWG is being used. Anti-Xa activity for Fragmin is 0.5-1.0 U/ml for continuous infusion with a reduction in dosage in renal failure to maintain the anti-Xa activity at 0.2-0.4 U/m!.
We report two patients who required an alternative to UFH for anticoagulation. In the first patient Lomoparan was administered via continuous infusion to maintain the extracorporeal circuit for CVVH. A recent publication reported the use ofORG 10172 in two patients with heparininduced thrombocytopenia. 23 In this report one patient received ORG 10172 for intermittent Graph of LMWH V. Anti Xa Activity haemodialysis and the other for cardiopulmonary bypass surgery. We are unaware of any literature regarding the use via continuous infusion of LMW glycosaminoglycuronans for CVVH. The peaks in the graph (Figure 1 ) are related to bolus doses given when new haemofilters were installed. The second patient received intermittent subcutaneous doses and the associated changes in coagulation are shown in Figure 2 . It is of interest to note that this patient had atrial thrombi suggesting inadequate in vivo total anticoagulant activity of intermittent subcutaneous dosing which nevertheless provided adequate anticoagulation for the extracorporeal circuits used for intermittent haemodialysis.
